ARM HOLDINGS PLC /UK (ARM) Spending and interest coverage
- R&D / revenue · 12 months: Value 57.49%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 22.38%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 57.49% | Research and development expense / revenue. Period ending 2026-06-30. $2.96B ÷ $5.16B × 100 ≈ 57.49% |
| Stock-based compensation / revenue · 12 months | 22.38% | Share-based compensation / revenue. Period ending 2026-06-30. $1.15B ÷ $5.16B × 100 ≈ 22.38% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 2.96B USD | Research and Development Expense |
| Revenue | 5.16B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.15B USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 877.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.96B | $5.16B | $1.15B | $877.00M | (m) | 57.49% | 22.38% | (m) | (m) |
| 2026-03-31 | $2.78B | $4.92B | $1.05B | $900.00M | (m) | 56.42% | 21.38% | (m) | (m) |
| 2025-12-31 | $2.62B | $4.67B | $984.00M | $872.00M | (m) | 56.18% | 21.07% | (m) | (m) |
| 2025-09-30 | $2.42B | $4.41B | $926.00M | $862.00M | (m) | 54.85% | 20.99% | (m) | (m) |
| 2025-06-30 | $2.24B | $4.12B | $879.00M | $763.00M | (m) | 54.26% | 21.33% | (m) | (m) |
| 2025-03-31 | $2.07B | $4.01B | $820.00M | $831.00M | (m) | 51.68% | 20.46% | (m) | (m) |
| 2024-12-31 | $2.11B | $3.69B | $812.00M | $443.00M | (m) | 57.09% | 21.98% | (m) | (m) |
| 2024-09-30 | $2.01B | $3.54B | $784.00M | $402.00M | (m) | 56.80% | 22.18% | (m) | (m) |
| 2024-06-30 | $2.13B | $3.50B | $1.08B | $182.00M | (m) | 60.82% | 30.86% | (m) | (m) |
| 2024-03-31 | $1.98B | $3.23B | $1.04B | $111.00M | (m) | 61.21% | 32.08% | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $1.13B | $2.68B | $79.00M | $671.00M | (m) | 42.29% | 2.95% | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $995.00M | $2.70B | $26.00M | $633.00M | (m) | 36.81% | 0.96% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.